ArticleInternational journal of clinical oncology2026
Association between ABCB1 genetic polymorphisms with treatment outcomes in patients with metastatic pancreatic cancer.
Article in International journal of clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGemcitabine plus nanoparticle albumin-bound-paclitaxel (GnP) therapy cause sometimes severe neutropenia in all the treatment period, which was reported to association with overall survival (OS). However, the relationship between pharmacokinetics-related genetic polymorphisms and both OS and early severe neutropenia in patients with metastatic pancreatic cancer receiving GnP therapy has not been adequately examined. We aimed to examine the associations between pharmacokinetic genetic polymorphisms involved in GnP, early severe neutropenia, and OS in Japanese patients with metastatic pancreatic cancer treated with GnP as first-line chemotherapy.
methodsThis multicenter prospective observational study enrolled 122 patients with metastatic pancreatic cancer who received GnP therapy. Twenty-two genetic polymorphisms related pharmacokinetics of GnP including ABCB1 were analyzed. Multivariable logistic regression and time-dependent Cox proportional hazards models were used to evaluate associations between these genotypes and early severe neutropenia up to day 14 and OS after applied inverse probability of treatment weighting. The significance level was set at 5%.
resultsPatients who developed early severe neutropenia had significantly longer median OS (523 vs. 249 days; adjusted hazard ratio [HR], 0.47; 95% confidence interval, 0.26-0.85; p = 0.012). The combination of ABCB1 rs2032582 non-GG and rs1045642 non-CC were significantly associated with severe neutropenia (adjusted odds ratio, 2.75; p = 0.020) and OS (adjusted HR, 0.56; p = 0.017).
conclusionsEarly-onset severe neutropenia could be associated with prolonged OS in patients with metastatic pancreatic cancer treated with GnP. The combination of ABCB1 rs2032582 non-GG and rs1045642 non-CC may help predict the risk of severe neutropenia and OS.
trial registrationUMIN 000012720.
Indexed as
Identifiers
42762424What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.